PacBio Gains Foothold in SUDC Research with First-Line Sequencing

Event summary

  • PacBio’s HiFi long-read sequencing technology will be used as the initial diagnostic approach for Sudden Unexplained Death in Childhood (SUDC) research.
  • The research effort is led by Danny Miller, MD, PhD, and Alexandra Keefe, MD, PhD, at UW Medicine and Seattle Children’s, and backed by the SUDC Foundation.
  • The University of Washington team will join the HiFi Solves Global Consortium to study the broader clinical applications of HiFi sequencing.
  • The initiative aims to improve diagnostic yield by resolving complex genetic variants, including structural variants and tandem repeats, by incorporating parental data.

The big picture

This collaboration represents a strategic win for PacBio, positioning its HiFi technology in a high-value, emotionally charged area of clinical diagnostics. The SUDC Foundation’s backing and the University of Washington’s involvement lend significant credibility to the technology’s potential. While the SUDC market itself is relatively small, successful application here could serve as a proof-of-concept for broader adoption in rare disease diagnostics, a market with significant unmet need and potential for growth.

What we're watching

Clinical Adoption
The success of HiFi sequencing in SUDC research could accelerate its adoption in other rare disease diagnostics, potentially expanding PacBio’s addressable market beyond research applications.
Regulatory Pathway
The use of HiFi sequencing in clinical diagnostics will likely face regulatory scrutiny, and the speed of approval will impact PacBio’s ability to commercialize the technology in this area.
Competitive Landscape
Other sequencing technologies may challenge HiFi’s position as the first-line assay, and PacBio’s ability to maintain a cost and performance advantage will be critical for sustained adoption.